Company page

Bridgebio Pharma, Inc.

Bridgebio Pharma, Inc. is a public company traded under the ticker BBIO in the American market. With a market capitalization of approximately $16.47 billion, the company focuses on developing innovative therapies for genetic diseases and cancers. Bridgebio aims to address significant unmet medical needs through its research and development efforts.